Real-world evaluation of effectiveness, persistence and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/48796
• EU PAS number:
  EUPAS39635
• Study ID:
  48796
• Official title and acronym:
  Real-world evaluation of effectiveness, persistence and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
• DARWIN EU® study:
  No
• Study countries:
  Australia
• Study description:
  To understand the treatment patterns, clinical effectiveness, patient reported outcomes and treatment persistence among Australian adult patients with psoriatic arthritis
• Study status:
  Finalised

Research institution and networks

Institutions

Pfizer

OPAL Rheumatology Limited

Study timelines

Date when funding contract was signed

Planned: 01/03/2020

Actual: 29/06/2020

Study start date

Planned: 31/05/2021

Actual: 15/05/2021

Date of final study report

Planned: 01/11/2022

Actual: 28/08/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Study protocol

Initial protocol

A3921398 Final Non-Interventional Protocol Study Abstract

Updated protocol

A3921398 Non-Interventional Study Protocol 04 March 2021

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable